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Objective: The purpose of this study was to determine the risk factors
associated with the occurrence of perigraft seromas complicating systemic-
to-pulmonary polytetrafluoroethylene grafts. Methods: Clinical and periop-
erative variables were reexamined, blinded for the outcome variable
perigraft seroma, in 60 patients undergoing 67 consecutive graft procedures
in a 3.5-year period. Results: Eight cases of perigraft seroma were diagnosed
in six patients. Univariate analysis revealed age (p 5 0.02), a diagnosis of
pulmonary atresia with ventricular septal defect and systemic–pulmonary
collaterals (p 5 0.001), reimplantation of collaterals during the procedure
(p < 0.001), and intravenous heparin administered after operation (p <
0.0001) as risk factors for symptomatic perigraft seroma. Multivariable
analysis defined heparin as the only significant factor associated with
symptomatic perigraft seroma. Consolidation of the upper lobe on chest
radiograph, ipsilateral to the shunt, directly after operation (p 5 0.01), but
especially 8 to 10 days after operation (p < 0.0001), or the need for
prolonged drainage of pleural fluid (p < 0.0001) were correlated with the
occurrence of perigraft seroma. Perigraft seroma led to four early retho-
racotomies in three patients and to accelerated corrective surgery in three
cases. Consolidation and absent perfusion of lung segments persisted in
two patients. Conclusions: Our data suggest that the use of heparin leads to
an increased risk of perigraft seroma, complicating systemic–pulmonary
polytetrafluoroethylene grafts. Prolonged pleural drainage and/or postop-
erative consolidation of the upper lobe indicate the development of symp-
tomatic perigraft seroma. Treatment is controversial and results are unpre-
dictable. Expectative management seems to be justified so long as permitted by
the clinical condition. (J Thorac Cardiovasc Surg 1998;116:286-93)
Systemic-pulmonary polytetrafluoroethylene (PTFE)grafts, like the modified Blalock-Taussig (MBT)
shunts, are of major importance in the management of
infants and children with various congenital heart
diseases.1 The MBT shunt provides the possibility to
create pressure- and volume-controlled pulmonary
perfusion with preservation of distal flow in the sub-
clavian artery. It has extended the surgical options in
the treatment of children with cyanotic heart disease.
Reported complications of the MBT shunt are throm-
bosis, infection, and pseudoaneurysm of the graft.2, 3
An unusual and infrequently reported complication of
the PTFE graft is a perigraft seroma.2, 4 This “clinico-
pathologic entity, manifested by a persistent, often
enlarging, sterile fluid collection confined within a
nonsecretory, fibrous pseudomembrane around a
prosthetic graft” can seriously complicate the clinical
outcome in patients.4 Because of compression of the
lung, this complication may cause loss of lung tissue
and functional pulmonary vasculature. Especially in
patients with pulmonary atresia (PA), ventricular sep-
tal defect (VSD), systemic–pulmonary collateral arter-
ies, and a hypoplastic pulmonary artery system, this is
a major threat because the prerequisite for surgical
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correction, being an adequately unifocalized pulmo-
nary artery system, may be jeopardized.5, 6 However,
knowledge on perigraft seroma is limited; reports on
management are infrequent, and early recognition
may be difficult. In our series of 60 patients with 67
MBT shunts we diagnosed eight cases of symptomatic
perigraft seroma in six patients. Clinical presentation,
associated variables, and outcome will be described.
Further, possible etiologic factors will be discussed.
Patients and methods
Data of all patients who underwent an MBT procedure
with a PTFE graft in our institution between January 1993
and May 1996 were reexamined. Clinical variables (age,
sex, diagnosis) and perioperative variables (diameter of
the graft, reimplantation of collaterals into the native or
newly reconstructed pulmonary artery in patients with PA
and VSD, postoperative heparin administration) were
retrospectively studied, with the occurrence of perigraft
seroma as outcome variable. All chest radiographs, echo-
graphic studies, and computed tomographic (CT) and
magnetic resonance imaging (MRI) scans were reexam-
ined by investigators blinded for the outcome variable. All
MBT shunts were constructed through a posterolateral
thoracotomy at the fourth intercostal space. The MBT
shunt was constructed either as an isolated procedure or
as part of a unifocalization procedure. Interposition of a
PTFE graft,* diameter 4 mm (n 5 2), 5 mm (n 5 61), or
6 mm (n 5 4), between the systemic and pulmonary
circulations, was performed with a 7-0 polypropylene
(Prolene; Ethicon, Inc., Somerville, N.J.) continuous su-
ture for both anastomoses. The chest was drained by
single-tube drainage. On postoperative day 1, the decision
was made whether to remove the drain. In the case of
persistent pleural fluid leakage or pneumothorax, the
chest tube was left in place as long as required. Antico-
agulants were not administered routinely. Unifocalization
procedures involving reimplantation of systemic–pulmo-
nary collateral arteries on the native or newly constructed
pulmonary artery were regarded as an indication for
anticoagulant therapy. In these cases, intravenous heparin
administration was started directly after the operation,
aiming at a two- to threefold increase in activated partial
thromboplastin time. Subsequently, oral coumarin ther-
apy was continued for 3 months. Also in cases of heparin
treatment for thromboembolic events not related to the
operative procedure, heparin therapy was continued in
the postoperative period. In all patients, a chest radio-
graph was made within the first 24 hours after operation
and 8 to 10 days after the procedure. In cases of persisting
consolidation of the ipsilateral upper lobe or persisting
leakage of pleural fluid (.48 hours), thoracic echography
was performed. A CT or MRI scan was performed only
when clinical suspicion of a symptomatic perigraft seroma
was present. The diagnosis of perigraft seroma was con-
firmed during subsequent surgical procedures.
Statistical analysis. The results were subjected to uni-
variable and multivariable analyses. For continuous vari-
ables, comparisons between patients with and without
perigraft seroma were made with the Student’s t test or
the Mann-Whitney test when a nonparametric test was
indicated. For categoric variables, comparisons were
made with the Fisher exact test. Exact logistic regression
analysis (LogXact; Cytel Software Corporation, Cam-
bridge, Mass.) was used to evaluate the various factors
simultaneously regarding the occurrence of perigraft se-
roma. It was verified that the findings were not essentially
affected by the outcomes of the second graft procedure for
those seven patients who had two graft procedures.
Results
In the study period, 67 MBT shunts with PTFE
grafts were constructed in 60 patients. Of these, 36
were male. Seven of the 60 patients received two
PTFE grafts: five because of consecutive unifocal-
ization procedures on both sides, one because of
pulmonary coarctation, and one because of throm-
bosis of the previous graft. Patient characteristics
and diagnoses are shown in Table I. Eight of 60
patients died 3 to 273 days after the operation
* Gore-Tex graft, registered trademark of W. L. Gore & Associ-
ates, Inc., Elkton, Md.











Reimplantation of SPCAs 10 13 6 (46) 52 (13-105)
Ligation of SPCAs 8* 9 1 (11) 13 (1-49)
Obstructed pulmonary flow in biventricular or univentricular heart 22 23 1 (4) 1 (0.1-9)
Tetralogy of Fallot 12 13 0 0.7 (0.1-4)
Hypoplastic pulmonary artery branch 6 6 0 13 (5-102)
Transposition of the great arteries and involuted LV 3 3 0 1.5 (1-2)
Total 60 67 8 (12%) 9 (0.1-105)
PA, Pulmonary atresia; VSD, ventricular septal defect; SPCA, systemic–pulmonary collateral artery; LV, left ventricle; PGS, perigraft seroma; PTFE,
polytetrafluoroethylene.
*One patient had two unifocalization procedures, with left-sided reimplantation of collateral arteries on one occasion and right-sided ligation of collateral
arteries on the other occasion.
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(median 60 days). No patient died of MBT proce-
dure–related causes. We diagnosed a total of eight
symptomatic perigraft seromas in six patients. All
seromas were confirmed during subsequent surgical
procedures. The age was higher in patients diag-
nosed with perigraft seroma compared with those
without perigraft seroma (median 28 months, range
0.2 to 67 months, versus median 2 months, range 0.1
to 105 months; p 5 0.02). Univariate analysis of the
other variables is shown in Table II. Perioperative
intravenous heparin therapy was administered in 14
procedures, either because of reimplantation of
systemic–pulmonary collateral arteries (n 5 8), ar-
bitrarily estimated increased risk of thromboembolic
complications (n 5 2), or perioperative thromboem-
bolic events not related to the MBT shunt (n 5 4).
The heparin dose ranged from 6 to 20 IU/kg per
hour; the duration of intravenous heparin adminis-
tration ranged from 2 to 24 days (median 4.5 days).
Four patients received coumarin without previous
heparin therapy; symptomatic perigraft seroma de-
veloped in none of these patients. Table III shows
the results of the multivariate analysis of various
clinical and perioperative variables regarding the
occurrence of symptomatic perigraft seroma. Ad-
justed for the other factors, heparin medication
showed to be an independent predictor for symp-
tomatic perigraft seroma (odds ratio 18.8; 95%
confidence interval 1.2 to .100). None of the other
factors showed a significant association with peri-
graft seroma. The same conclusions were reached
when each of these variables was analyzed sepa-
rately, only taking account of heparin use. All the
significant (univariate) associations with perigraft
seroma (Table II), months of age, the diagnosis of
PA, VSD, and systemic–pulmonary collateral arter-
ies, and reimplantation of systemic–pulmonary col-
lateral arteries could be explained by the relation of
these variables with heparin use. Although for chil-
Table II. Univariate analysis of clinical and
perioperative variables
PGS/






Male 7/41 5.0 0.6-.100 0.14
Age
#1 year 1/43 1
.1 year 7/24 16.5 1.9-.100 0.002
Diagnosis of PA, VSD,
SPCAs
No 1/45 1
Yes 7/22 19.5 2.2-.100 0.001
Graft diameter
4 mm 0/2 0.0 0.0-11.8 0.47
5 mm 6/61 0.1 0.0-1.8 0.07
6 mm 2/4 1 1.5-18.2
Reimplantation of SPCAs
No 2/54 1
Yes 6/13 20.5 3.0-.100 0.0004
Heparin
No 1/53 1






Yes 5/15 7.8 1.3-58.7 0.01
8-10 Days postoperatively
No 2/56* 1
Yes 6/9 50.0 5.6-.100 ,0.0001
Duration of chest-tube
drainage
#48 hr 2/58 1
.48 hr 6/9 47.7 5.8-.100 ,0.0001
OR, Odds ratio; 95% CI, 95% confidence interval of odds ratio; PA,
pulmonary atresia; VSD, ventricular septal defect; SPCA, systemic–pulmo-
nary collateral artery.
*Two patients died before the eighth to tenth postoperative day.
Table III. Multiple logistic regression analysis of
various clinical and peroperative variables regarding
the occurrence of PGS
Variable OR 95% CI p Value
Heparin
No 1
Yes 18.8 1.2-.100 0.02
Diagnosis of PA, VSD,
SPCAs
No 1
Yes 1.2 0.0-.100 1.0
Graft diameter
4 mm 5.5 0.0-.100 1.0




Yes 5.8 0.1-.100 0.78
Sex
Female 1
Male 7.3 0.2-.100 0.47
Age
#1 year 1
.1 year 0.4 0.0-.100 1.0
Reference categories are indicated with an odd’s ratio of 1. OR, Odds
ratio; 95% CI, 95% confidence interval of odds ratio; PA, pulmonary
atresia; VSD, ventricular septal defect; SPCA, systemic–pulmonary collat-
eral artery.
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dren older than 1 year of age the percentage of
heparin use was 42% (10/24 patients), this percent-
age was only 9% (4/43 patients) for infants who were
younger than 1 year of age. Also, in case of reim-
plantation of systemic–pulmonary collateral arteries
the percentage of heparin use was high, namely 62%
(8/13 patients), whereas this percentage was 11%
(6/54 patients) for other patients. In case of a
diagnosis of PA, VSD, and systemic–pulmonary
collateral arteries, heparin was used in 46% of the
cases (10/22 patients), as compared with 9% (4/45
patients) for the patients with other diagnoses.
The duration of postoperative chest tube drainage
for pleural fluid leakage was prolonged in patients
with perigraft seroma compared with those without
perigraft seroma (median 134 hours, range 20 to 600
hours, versus median 20 hours, range 0 to 120 hours;
p , 0.0001). A chest radiograph revealing pleural
fluid within 24 hours after the procedure was not
correlated significantly with a diagnosis of perigraft
seroma. However, three patients still showed pleural
fluid on their chest radiograph 8 to 10 days after the
procedure; perigraft seroma was diagnosed in two of
these patients (p 5 0.04). A consolidation of the
ipsilateral upper lobe, directly after operation, but
even more after 8 to 10 days, was associated signif-
icantly with the diagnosis of perigraft seroma (Table
II). All patients who showed a persistent consolida-
tion of the ipsilateral upper lobe or who required
pleural fluid drainage by chest tube for more than 48
hours underwent echographic evaluation of the in-
volved area (n 5 12). In eight cases in which
subsequently perigraft seroma was diagnosed, tho-
racic echography revealed an avascular, inhomoge-
neous echogenic area accompanied by compression
of lung tissue and pleural fluid (n 5 3); an avascular,
echolucent cystic process (n 5 2); an echolucent,
pulsating mass (n 5 1); isolated pleural fluid (n 5
1), or no abnormalities (n 5 1). The relation of
these abnormal areas to the graft could not be
determined echographically. In the remaining four
patients, thoracic echography revealed isolated
compression of apical lung tissue, suggesting atelec-
tasis. CT or MRI was performed in four patients in
whom there was a clinical suspicion of perigraft
seroma. In all four patients CT/MRI revealed a
hypodens, cystic structure, adjacent to the graft in
which no flow could be detected. In two of these
four patients, such a structure was also detected
adjacent to a previous PTFE graft. In retrospect, in
both these patients the first graft procedure was
followed by radiographically persistent consolida-
tion of the ipsilateral upper lobe and one of the two
had prolonged pleural fluid drainage. Echography in
that period had revealed isolated pleural fluid in one
case and no abnormalities in the other. So, six of the
eight described cases of symptomatic perigraft se-
roma were documented by CT or MRI scanning.
Progressive respiratory distress forced us to reop-
eration in three patients, respectively 8, 14, and 25
days after the MBT procedure. In these patients,
through a lateral rethoracotomy, the seroma was
removed and the PTFE graft was left in place. In
one of these patients the graft was additionally
sealed with fibrin glue (Tissucol Duo 500; Immuno
AG, Vienna, Austria). A consolidation of the upper
lobe on chest radiograph recurred within 2 days in
all three cases, leading to recurrence of respiratory
distress in two patients. After the reintervention, all
three patients required chest tube drainage for more
than 48 hours because of pleural fluid production. In
two patients the chest tube could be removed after
72 hours. Both patients gradually improved clini-
cally. The third patient, in whom the graft was
sealed with fibrin glue, needed a second rethora-
cotomy because of persisting pleural fluid produc-
tion and respiratory distress, 35 days after the first
rethoracotomy. A recurrent seroma was removed.
This time the graft was sealed with microfibrillar
collagen (Lyostypt; B. Braun Melsungen AG, Mel-
sungen, Germany) and Histoacryl tissue adhesive
(B. Braun Melsungen AG). At follow-up, of the
patients who underwent one rethoracotomy, one
patient showed spontaneous resolution of clinical
and radiologic features and underwent corrective sur-
gery 12 months after the MBT procedure. The other
two patients both showed a persistent consolidation of
the upper lobe on chest radiograph and an absent
perfusion of the apical area on pulmonary artery
angiography at 27 and 24 months of follow-up, respec-
tively. In one of these two patients, surgical correction
could be completed. In three other cases, the perigraft
seroma led to accelerated surgical correction of PA,
VSD, and systemic–pulmonary collateral arteries (two
cases) and PA with intact ventricular septum (one
case), with removal of the seromas and ligation of the
grafts. These three patients recovered completely, with
no sequelae at follow-ups of 4, 9, and 15 months,
respectively. Finally, in two cases there was spontane-
ous resolution of clinical and chest radiographic fea-
tures, except for a widening of the superior mediasti-
num on chest radiography as an isolated finding in one
case. Elective correction was performed respectively
12 and 23 months after the MBT procedure.
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Discussion
The occurrence of a perigraft seroma can compli-
cate the clinical outcome of patients undergoing an
MBT procedure with a PTFE graft. The reported
incidence of perigraft seroma needing treatment
varies from 0.5 to 2.5%.2, 3, 7 However, the true
incidence of perigraft seroma is unknown because a
number of cases of perigraft seroma probably re-
main undetected. This is illustrated by a study in 29
adult, asymptomatic patients who underwent an
abdominal CT scan after uncomplicated abdominal
aortic reconstruction, in which seven cases of peri-
graft seroma were detected (24%).8 Leakage of
serous fluid from PTFE grafts is reported to have a
significant higher incidence, up to 20%.7 In our
series the incidence of a symptomatic perigraft
seroma was 12% (95% confidence interval 5% to
22%). This high incidence may be related with the
selection of our patient group. Because of a protocol
adopted in 1991 in our institution for the perfor-
mance of staged total surgical correction of patients
with PA, VSD, hypoplastic pulmonary arteries, and
systemic–pulmonary collateral arteries by subse-
quent unifocalization procedures, the patients com-
prise a relatively large and somewhat older group in
our study.
Most frequently complicated by perigraft seroma
are the knitted Dacron grafts, directly followed by
PTFE grafts.4 Autografts do not seem to be affected
by this complication.4, 9 The cause of perigraft se-
roma is unknown. Various theories have been pos-
tulated, trying to explain the pathogenetic mecha-
nism involved in the formation of perigraft seroma.
The hydrophobic surface of PTFE is converted in a
hydrophilic one, when in contact with blood or
interstitial fluid, the so-called “wetting” process.9, 10
On the other hand deposition of proteins and
attachment of fibrous tissue, both externally and
internally, causes a “sealing” of the graft surface.4, 9
In perigraft seroma the surrounding connective tis-
sue fails to incorporate the graft, probably as a result
of an imbalance between the “wetting” and “seal-
ing” process. One reason for this imbalance may be
mechanical forces, altering the architecture of the
graft by increasing the distance between the PTFE
fibers and thereby diminishing its water-repellent
properties. The theoretic relationships among inter-
fibrillar distance, intraluminal pressure, and graft
leakage were demonstrated in a computer simula-
tion by Tabata and coworkers.11 This would have
direct implications for graft handling before and
during the operation, such as stretching, bending,
clamping, and compression of the graft. However,
we found no differences in perioperative graft han-
dling. According to this hypothesis, hemodynamic
forces could be involved in the development of
perigraft seroma. In our series age was associated
with perigraft seroma in the univariate analysis. One
could speculate that in older patients, with higher
blood pressures, a higher mean pressure in the graft
may lead to extravasation of fluid through the graft
wall. However, age did not retain significance in the
multivariable analysis, although in view of the wide
confidence intervals its effect cannot be excluded
from our data.
Histologic evidence of perigraft seroma has
shown a fibrous pseudomembrane lining the seroma
wall and immature fibroblasts lining the graft. In
portions of the graft not involved with the seroma, a
thicker and more densely adherent fibroblast layer
has been observed.4 These observations have led to
a theory of fibroblast inhibition as a mechanism
leading to perigraft seroma formation. Studies of
Sladen,12 Ahn,3, 13 Schneiderman,14 and their asso-
ciates suggest the presence of a humoral fibroblast
inhibitor in the serum of patients in whom perigraft
seroma is developing. This inhibitor could prevent
the maturation and proliferation of perigraft fibro-
blasts, leading to poor graft incorporation.3, 12 After
removal of the grafts, the fibroblast inhibitory prop-
erties of serum of these patients decreased below
detectable levels, suggesting that the graft may
induce host production of such an inhibitor.3 Fur-
thermore, it seems that this humoral factor can be
cleared by plasmapheresis.12 A third cause for an
disbalance between wetting and sealing may be the
exposure of the graft to agents that diminish water
repellency and thereby accelerate the wetting pro-
cess. These agents include organic solvents, povi-
done iodium, antibiotic solutions, blood, and tissue
fluids.9-11 In contrast to the findings of Leblanc and
associates,7 our study suggests an important role for
intravenously administered heparin in the develop-
ment of perigraft seroma. Reimplantation of collat-
erals did not prove to be an independent risk factor.
The same applied to the diagnosis PA, VSD, and
systemic–pulmonary collateral arteries. One could
speculate that heparin in the direct postoperative
period impairs fibrin formation in the interstices of
the PTFE graft wall and thereby disturbs the sealing
process of the graft. Since the introduction, in the
course of 1993, of our policy to provide heparin
therapy for patients undergoing unifocalization pro-
cedures with reimplantation of systemic–pulmonary
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collateral arteries, we diagnosed eight cases of peri-
graft seroma in 60 patients in a 3.5-year period.
Before this policy we did not observe any symptom-
atic perigraft seromas, despite numerous PTFE
graft implantations. Although our policy induced a
selection regarding the use of postoperative heparin,
the multivariable analysis, taking account of the
confounding factors, indicated that heparin use was
an independent risk factor.
In our series, pleural fluid production, requiring
chest tube drainage for more than 48 hours, was
suggestive for the development of symptomatic peri-
graft seroma. A consolidation of the apical lung field
at the side of the implanted graft on the chest
radiograph, directly after operation, but even more
8 to 10 days after the procedure, was predictive of
the presence of a perigraft seroma. However, differ-
entiation with atelectasis, hematoma, or pseudoan-
eurysm can be difficult.7 Echocardiography has been
reported to be useful in the identification of a
thoracic mass and determination of its relation with
arterial structures and the lung.15 In our experience,
however, this differentiation appeared to be cum-
bersome. Thoracic CT/MRI scanning, performed in
four of our patients, clearly demonstrated the pres-
ence of a cystic formation, without pulsatile flow,
and its relation to the graft and the surrounding
structures. The six perigraft seromas diagnosed with
CT/MRI scanning were all confirmed surgically,
indicating that CT/MRI revealed no false-positive or
false-negative findings in these patients. Reported
complications of perigraft seroma include infection,
graft thrombosis, and reoperation.3 Further, peri-
graft seroma can lead to compression and atelectasis
of the upper lung lobe. Persisting compression of
adjacent structures can result in a loss of functional
lung tissue and the vasculature of the involved lobe,
as shown by two of our patients. This complication is
especially harmful in patients undergoing unifocal-
ization procedures, aiming at an optimalization of
the pulmonary vascular bed.5, 6 Therapy of symp-
tomatic perigraft seroma is controversial. Because
of the high incidence (65%) of spontaneous resolu-
tion of perigraft seroma, described in selected cas-
es,4 expectative management seems to be justified.
In symptomatic cases, however, intervention may be
indicated because of progressive respiratory failure.
Resection and aspiration of the perigraft seroma
both are complicated by a high rate of recurrence
and infection.4, 16 Total graft removal, although ef-
fective,3, 4 requires not only another surgical proce-
dure to provide pulmonary flow but, even more
important, use of new graft material. Other thera-
peutic options are based on enhancement or forti-
fication of protein deposition to stop the leakage.9
This has been tried by wrapping the graft with
absorbable collagen hemostat (Novacol Fibrillar) or
collagen fleece soaked in fibrin glue,17, 18 topical
application of microfibrillar collagen or Histoacryl
tissue adhesive,19, 20 and intraluminal injection of a
solution containing aprotinin, thrombin, and cal-
cium chloride.21 As illustrated by our patients, these
methods do not necessarily prevent recurrence or
complications of the perigraft seroma. Two of our
patients showed persisting compression of lung tis-
sue and loss of functional pulmonary vasculature,
despite surgical removal of the perigraft seroma.
Finally, plasmapheresis has been reported as a
strategy, based on the hypothesis of a humoral
fibroblast inhibitor.12 Although this technique has
shown to be successful in few patients, it has not
been confirmed in clinical trials.
Limitations of the study. A retrospective study
has inherent shortcomings. Heparin was not admin-
istered at random, but on arbitral grounds. More
than one half of the patients received heparin
therapy because of reimplantation of collaterals.
However, the outcome of the multivariable analysis
suggests patients who received heparin therapy had
an increased risk of perigraft seroma. It has to be
acknowledged that, because of a small number of
events and, consequently, the wide confidence inter-
vals, the effects of the other variables associated with
perigraft seroma in the univariate analysis cannot be
excluded. The study design does not allow a definite
conclusion whether the relation between heparin
use and perigraft seroma is causal or just coinciden-
tal.
In conclusion, our data strongly suggest that,
administered postoperatively, intravenous heparin is
associated with an increased risk for symptomatic
perigraft seroma in patients undergoing MBT
shunts with PTFE grafts. Although we recognize the
potential beneficial effects of heparin in specific
circumstances, we advocate to consider this possible
adverse effect of heparin therapy after PTFE graft
implantation, especially if associated with reimplan-
tation of collaterals, when making decisions on its
use. Consolidation of the upper lobe, ipsilateral to
the shunt, on chest radiography directly after oper-
ation, but especially after 8 to 10 days, or prolonged
drainage of pleural fluid may alert to the develop-
ment of perigraft seroma. We believe CT or MRI
scanning is the imaging technique of choice to
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diagnose suspected perigraft seroma. This compli-
cation of the MBT procedure may lead to loss of
perfused lung segments. Treatment of perigraft se-
roma is controversial, and the results are unpredict-
able. Expectative management, even when accom-
panied by prolonged hospitalization, seems to be
justified so long as it is permitted by the clinical
condition.
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Commentary
This is a clinical study of 67 consecutive modified
Blalock-Taussig shunts in 60 patients. Eight cases of
perigraft seroma developed in six of these patients, and
this study is a retrospective evaluation of the variables that
might be most associated with the development of this
problem. The incidence of perigraft seroma in this study is
rather high (11.9%) compared with the incidence of 0.5%
to 2.5% referenced in the manuscript. Furthermore, in
our own practice, this is an extremely rare occurrence. In
117 aortopulmonary shunts placed since 1992 we have yet
to recognize and document a single case of perigraft
seroma. Therefore it is interesting that it is so “common”
in the authors’ experience. Furthermore, we frequently
use heparin in the perioperative period for all patients
who receive a polytetrafluoroethylene modified Blalock-
Taussig shunt; therefore it is concerning that the authors’
retrospective review has led somehow to misleading con-
clusions. It is interesting to note that the patients in this
study comprise a somewhat older group (mean age 9
months) who received generally larger shunts than what is
seen more commonly in this country. For example, only
two patients received 4 mm shunts and a vast majority of
patients received shunts that were 5 or 6 mm in diameter.
Interestingly, in the univariate analysis, shunt size did
appear to be associated with perigraft seroma as did age,
in that this finding was far more common in older patients
(seven of eight cases in those more than 1 year of age). It
is also interesting that the authors placed their shunts
through thoracotomies. This might lead to the division of
lymphatic vessels, which could also relate to the preva-
lence of perigraft seromas in their series. In our own
personal experience, shunts have been placed through a
median sternotomy since 1986, and the incidence of
recognized perigraft seroma has been 0%.
The authors have done the best they can with the data
they have. They have a fairly large number of perigraft
seromas and a relatively small number of patients, and it is
interesting that this complication does appear more fre-
quently in their patients who received heparin. Nevertheless,
heparin is a widely recognized perioperative therapy for
patients receiving aortopulmonary shunts. This is because
the incidence of graft thrombosis is much higher in most
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experiences than the incidence of perigraft seroma. The
authors administered heparin for a median of 4.5 days with
a range between 2 and 24 days. This duration of heparin
therapy may be longer than what is commonly practiced, and
it may be that their association is with the duration of
heparin therapy being long rather than with the use of
heparin per se in the immediate postoperative period.
Although the authors point to an association with the
use of heparin, there are several factors that may relate
more specifically to the incidence of this complication.
These may include the age of their patients, the size of the
shunts being used, the duration of heparin therapy, the
blood pressures that are generated in older patients, the
placement of shunts through a thoracotomy, or even the
off chance that some of the polytetrafluoroethylene used
in this study may have been “resterilized.” The association
with heparin may be true from a multivariate standpoint
but may not have really disclosed the actual mechanism by
which this complication develops.
The authors are honest in discussing the limitations of
this study and do make an important point regarding the
presence of upper lobe consolidation persisting on the
side ipsilateral to the shunt a week after the operation,
which may be an important clinical sign that the presence
of a perigraft seroma should be investigated. Perhaps the
incidence of this complication is greater than we suspect,
but the authors do point out that the patients in their
series were all symptomatic and therefore raised suspicion
by virtue of their clinical course. It is most important that
the practicing pediatric cardiac surgeon evaluate the risks
for and true incidence of perigraft seroma in his or her
own practice in relation to the risks of not providing
heparin for a limited time in the perioperative period after
placement of an aortopulmonary shunt, especially shunts
in the 3.5 and 4 mm diameters.
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Durham, N.C.
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